[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"leukemia-myelomonocytic-chronic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:leukemia-myelomonocytic-chronic":72},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,57,85],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":42,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100513772","clonal-hematopoiesis-of-immunological-significance-100513772",false,"NCT05969821","Clonal Hematopoiesis of Immunological Significance","Immuno-inflammatory Manifestations With or Without Clonal Hematopoiesis: Ambispective Cohort Study","CHIS","Inclusion Criteria:\n\n* Age \\>=18 years old;\n* Confirmed dysimmune manifestations: clinical or biological abnormality or systemic disease;\n* Presence or absence of myeloid or lymphoid blood disease according to World Health Organization (WHO) classification\n\nExclusion Criteria:\n\n* Persons benefiting from special protection: adults under guardianship and curatorship;\n* People hospitalized without their consent and not protected by law; persons deprived of liberty;\n* Persons not affiliated to the social security system","ALL","18 Years",{"count":20,"type":21},5000,"ESTIMATED","10 Years","OBSERVATIONAL","Ambispective, national, multicenter observational cohort study aimed at characterizing the satellite dysimmune manifestations of clonal hematopoiesis, including Vexas (Vacuoles, E1 enzyme, X-linked, Autoinflammatory and Somatic) syndrome.",[26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41],"Immune System Diseases","Autoimmune Diseases","Inflammation","Autoinflammatory Diseases","Vexas Syndrome","Hematopoiesis Clonal","Clonal Hematopoiesis of Indeterminate Potential","Hematologic Diseases","Myelodysplastic-Myeloproliferative Diseases","Leukemia Myelomonocytic Chronic","Myelodysplastic Syndromes","Myeloproliferative Disorders","Lymphoproliferative Disorders","Lymphoma","Leukemia","Monoclonal Gammopathy of Undetermined Significance",[28,29,43,27,32,34,38,41],"Vexas syndrome","NOT_YET_RECRUITING","2026-03-19",{"date":47,"type":48},"2026-03-23","ACTUAL",{"date":50,"type":21},"2026-04",{"date":52,"type":21},"2045-09",{"name":54,"class":55},"Assistance Publique - Hôpitaux de Paris","OTHER",1,{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":65,"targetDuration":4,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":84},"100595526","phase-2-pacritinib-vs-hydroxyurea-in-advanced-proliferative-chronic-myelomonocytic-leukemia-100595526","NCT07033598","Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia","A Randomized Phase 2 Study of Pacritinib vs. Hydroxyurea in Patients With Advanced Proliferative Chronic Myelomonocytic Leukemia","PROSPERA","Inclusion Criteria:\n\n* Diagnosis of CMML-1 (5th WHO classification), with \\\u003C10% bone marrow blasts on morphology and \\\u003C5% peripheral blood blasts.\n* Proliferative disease, defined as white blood cell count ≥13 × 10⁹\u002FL.\n* Advanced disease, defined as at least one of the following features during screening: spleen palpable ≥5cm below the lower costal margin in the midclavicular line; TSS ≥20; or platelet count \\\u003C100 × 10⁹\u002FL. For participants in whom spleen palpation is not feasible, an ultrasound exam may be performed for assessment of spleen craniocaudal length (length ≥12 cm by ultrasound is considered splenomegaly).\n* ECOG performance status ≤2.\n* Adequate organ function: AST and ALT ≤3 × ULN, total bilirubin ≤4 × ULN (≤8 × ULN in participants with Gilbert's syndrome), creatinine clearance \\>30 mL\u002Fmin, absolute neutrophil count ≥0.5 × 10⁹\u002FL, PT and PTT ≤1.5 × ULN.\n* Women of child-bearing potential must have a negative serum pregnancy test within 7 days prior to enrollment and, along with male participants, must agree to use a highly effective method of contraception from the first dose through 90 days after the last dose.\n\nExclusion Criteria:\n\n* Active malignancy diagnosed within the past 2 years, except for curatively treated non-invasive cancers (e.g., basal\u002Fsquamous cell skin cancer, low-risk prostate cancer on stable endocrine therapy with PSA stable ≥3 months).\n* Allogeneic hematopoietic stem cell transplant within 12 months prior to enrollment, or requiring immunosuppressive therapy within 6 months before enrollment.\n* Likely to undergo allogeneic hematopoietic stem cell transplant within 6 months, per investigator assessment.\n* Prior systemic treatment with any JAK inhibitor.\n* Treatment with hypomethylating agents or cytotoxic chemotherapy (excluding hydroxyurea) within 28 days prior to enrollment.\n* Participation in another interventional study or use of experimental therapy within 28 days or 5 half-lives, whichever is longer.\n* Use of hematologic support drugs within 28 days prior to enrollment. Supportive care permitted.\n* Use of strong CYP3A4 inhibitors or inducers within 14 days or 5 half-lives before enrollment, whichever is shorter.\n* Use of systemic anticoagulants or antiplatelets (except aspirin ≤100 mg\u002Fday) within 14 days prior. Therapeutic anticoagulation allowed if stable for ≥90 days without bleeding events.\n* CTCAE Grade ≥2 bleeding within 3 months prior to enrollment, unless due to a reversible cause (e.g., trauma, surgery).\n* QTcF \\>450 ms (men) or \\>470 ms (women); QTcF up to 480 ms allowed if QRS \\>100 ms. QTcF may be repeated if affected by reversible factors.\n* CTCAE Grade ≥3 cardiac event within 3 months before enrollment.\n* Symptomatic heart failure with limitations on ordinary activity.\n* Uncontrolled infection at study entry.\n* Moderate\u002Fsevere hepatic impairment (Child-Pugh B or C), or active viral hepatitis:\n* HBV: Exclude if HBsAg+ or HBV DNA detectable. HBV antiviral therapy allowed if HBV DNA undetectable.\n* HCV: Allowed if HCV Ab+ but RNA negative.\n* Uncontrolled HIV or detectable viral load while on antiretrovirals.\n* Known hypersensitivity to pacritinib or its excipients (microcrystalline cellulose, polyethylene glycol, magnesium stearate).",{"count":66,"type":21},66,"INTERVENTIONAL",[69],"PHASE2","The goal of this clinical trial is to learn if pacritinib works better than hydroxyurea to treat advanced proliferative chronic myelomonocytic leukemia in adults. The main questions it aims to answer are:\n\n* Does pacritinib improve disease control compared to hydroxyurea?\n* What medical problems do participants have when taking pacritinib or hydroxyurea? Researchers will compare pacritinib to hydroxyurea to see if pacritinib is more effective and better tolerated in people with advanced proliferative chronic myelomonocytic leukemia.\n\nParticipants will be randomly assigned to receive either pacritinib twice a day or hydroxyurea for up to 48 weeks.\n\nAfter treatment ends, participants will be followed for up to one year.",[72],"Leukemia, Myelomonocytic, Chronic","RECRUITING","2026-03-03",{"date":76,"type":48},"2026-03-05",{"date":78,"type":48},"2026-01-01",{"date":80,"type":21},"2028-12",{"name":82,"class":83},"Theradex","INDUSTRY",4,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":92,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":93,"conditions":94,"keywords":103,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":56},"100267393","myeloproliferative-neoplasms-mpns-patient-registry-100267393","NCT02760238","Myeloproliferative Neoplasms (MPNs) Patient Registry","Clinical and Molecular Epidemiology of Myeloproliferative Neoplasms (MPNs)","Inclusion Criteria:\n\nDiagnosis of one of the following myeloproliferative neoplasms (MPNs):\n\n* Atypical CML (aCML)\n* Chronic eosinophilic leukemia-not otherwise specified (CEL, NOS),\n* Chronic myelomonocytic leukemia (CMML)\n* Chronic neutrophilic leukemia (CNL),\n* Essential thrombocythemia (ET),\n* Juvenile myelomonocytic leukemia (JMML),\n* Mastocytosis, MPN unclassifiable\n* MPN\u002FMDS unclassifiable,\n* Primary myelofibrosis (PMF),\n* Post-essential thrombocythemia myelofibrosis (post-ET MF),\n* Post-polycythemia vera MF (post-PV MF)\n* Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T)\n\nExclusion Criteria:\n\n* None",{"count":20,"type":21},"The mandate of this MPN registry is to collect clinical information, including molecular results, from consenting patients with a variety of MPNs at different time points during the course of their disease.",[95,96,97,98,99,100,101,34,102,72],"Primary Myelofibrosis","Polycythemia Vera","Essential Thrombocythemia","Mastocytosis","Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative","Leukemia, Myelomonocytic, Juvenile","Chronic Eosinophilic Leukemia-not Otherwise Specified","Neoplasms",[104,105,106,107,108,33,102],"myeloproliferative neoplasm","myelodysplastic syndrome","registry","leukemia","Bone Marrow Diseases","2024-08-26",{"date":111,"type":48},"2024-08-27",{"date":113,"type":4},"2015-04",{"date":115,"type":21},"2027-10-31",{"name":117,"class":55},"University Health Network, Toronto"]